Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome (2018) Dillon J, Kulke M, Warner R, Bergsland E, Welin S, O'Dorisio T, Mckee C, et al. Conference contribution Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status (2018) Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt KH, Pavel ME, Wiedenmann B, et al. Conference contribution Medication safety in patients treated with new oral antitumor agents: A prospective, randomized investigation on the impact of intensified clinical pharmaceutical/clinical pharmacological care on patient safety, patient knowledge and patient well-being (AMBORA). Supported by the German Cancer Aid within the Comprehensive Cancer Center Erlangen-EMN (2018) Schlichtig K, Lechner P, Grafe C, Ferstl B, Fuchs F, Hein A, Meidenbauer N, et al. Conference contribution Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study (2018) Pavel ME, Denecke T, Lahner H, Hoersch D, Rinke A, Koch A, Liyanage N, et al. Conference contribution First Patient Survey about Tumor - Associated Fatigue in NEN (2018) Banz S, Mellar K, Letsch A, Scheibenbogen C, Pavel ME, Grabowski P Conference contribution Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al. Journal article Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome (2017) Pavel ME, Gable J, Kulke MH, Bergsland E, Anthony LB, Caplin ME, Oberg KE, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study (2017) Hoersch D, Raderer M, Lahner H, Rinke A, Denecke T, Koch A, Raspel A, et al. Conference contribution Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017) Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, et al. Journal article